Larson Yi

SEC source: 0001785987-26-000002 · form4-06232026_090642.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017240 · form4-06132025_050629.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017446 · form4-06182024_050616.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-005516 · form4-02272024_090250.xml · derivative · entry 3

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,848 shares

Expires 2032-11-30

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

SEC source: 0001415889-24-005516 · form4-02272024_090250.xml · derivative · entry 2

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,332 shares

Expires 2031-09-28

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

SEC source: 0001415889-24-005516 · form4-02272024_090250.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 59,399 shares

Expires 2031-03-18

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

SEC source: 0001415889-23-010106 · form4-06212023_050623.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001831283-23-000051 · wf-form4_168029382182313.xml · nonDerivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,901

F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0001831283-23-000018 · wf-form4_167459472625760.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464,099

Underlying: Ordinary Shares · 464,099 shares

Expires 2033-01-20

F1 · derivative.exercise_date: 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0001415889-22-006965 · form4a-06272022_020657.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006787 · form4-06172022_040602.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000899243-21-046751 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,202,841

Underlying: Ordinary Shares · 5,996 shares

Expires 2031-12-01

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on December 1, 2022; the remainder shall vest and become exercisable in three equal annual installments such that the option shall be fully vested on December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042213 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,196,845

Underlying: Ordinary Shares · 229,538 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in three equal annual installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0001415889-21-002924 · form4-06102021_030654.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2031-06-08

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-21-001923 · form4-04062021_040412.xml · derivative · entry 2

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,773

Underlying: Common Stock · 3,773 shares

Expires 2031-04-04

F2 · derivative.exercise_date: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-21-001923 · form4-04062021_040412.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2031-04-04

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from April 5, 2021, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-21-009370 · doc4.xml · derivative · entry 2

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,775

Underlying: Common Stock · 20,775 shares

Expires 2031-02-07

F2 · derivative.exercise_date: 1/48th of the shares vest monthly following February 8, 2021.

SEC source: 0001209191-21-009370 · doc4.xml · nonDerivative · entry 1

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,321

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.

SEC source: 0001209191-21-007037 · doc4.xml · derivative · entry 13

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,397

Underlying: Common Stock · 14,298 shares

Expires 2029-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F12 · derivative.exercise_date: 25% of the shares vested on August 26, 2020 with the remaining shares vesting in equal monthly installments over the following three years thereafter.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 11

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,704

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F11 · price: The weighted average sale price for the transaction reported was $131.73, and the range of prices were between $131.38 and $132.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 10

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,761

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F10 · price: The weighted average sale price for the transaction reported was $130.58, and the range of prices were between $130.25 and $131.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 9

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,028

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F9 · price: The weighted average sale price for the transaction reported was $129.80, and the range of prices were between $129.215 and $130.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 8

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,602

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F8 · price: The weighted average sale price for the transaction reported was $128.41, and the range of prices were between $128.12 and $128.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 7

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,002

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F7 · price: The weighted average sale price for the transaction reported was $127.58, and the range of prices were between $127.00 and $127.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 6

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,002

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

SEC source: 0001209191-21-007037 · doc4.xml · derivative · entry 12

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,695

Underlying: Common Stock · 15,702 shares

Expires 2029-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F12 · derivative.exercise_date: 25% of the shares vested on August 26, 2020 with the remaining shares vesting in equal monthly installments over the following three years thereafter.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 5

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,704

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F6 · price: The weighted average sale price for the transaction reported was $126.07, and the range of prices were between $125.58 and $126.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 4

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,904

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F5 · price: The weighted average sale price for the transaction reported was $124.60, and the range of prices were between $124.34 and $125.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 3

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,047

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F4 · price: The weighted average sale price for the transaction reported was $123.70, and the range of prices were between $123.29 and $124.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 2

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,623

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F3 · price: The weighted average sale price for the transaction reported was $122.94, and the range of prices were between $122.28 and $123.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007037 · doc4.xml · nonDerivative · entry 1

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,406

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.

F2 · balance_after: The Reporting Person acquired 86 shares on June 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 396 shares on December 10, 2020 pursuant the ESPP.

SEC source: 0001209191-20-002512 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2030-01-05

F1 · derivative.exercise_date: 1/48th of the shares will vest each month following January 6, 2020, so that all of the shares are vested four (4) years after January 6, 2020.

SEC source: 0001209191-19-049153 · doc4.xml · nonDerivative · entry 1

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,222

F1 · kind: The shares were purchased in connection with the Issuer's public offering.

SEC source: 0001209191-19-047510 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,397

Underlying: Common Stock · 312,397 shares

Expires 2029-08-25

F1 · derivative.exercise_date: 25% of the shares vest on August 26, 2020 with the remaining shares vesting in equal monthly installments over the following three years thereafter.